Anzeige
Erschienen in:
01.12.2012 | Urology - Original Paper
Determinants of outcomes after resection of renal cell carcinoma with venous involvement
Erschienen in: International Urology and Nephrology | Ausgabe 6/2012
Einloggen, um Zugang zu erhaltenAbstract
Purpose
To determine the outcomes and to identify prognostic variables determining mortality and recurrence after surgery for renal cell cancer (RCC) with venous involvement.
Methods
Retrospective evaluation of the medical records of 132 patients with RCC and tumor thrombi treated at Johns Hopkins Hospital (1997–2008) was done. Kaplan–Meier analysis was used to determine survivals. Uni- and multivariate Cox proportional analysis was done to identify predictors for recurrence, all-cause mortality (ACM) and cancer-specific mortality (CSM).
Results
Mean follow-up was 30.3 (0.03–159.5) months. Sixty-four (48.5 %) patients had renal vein thrombus (Group 1), 55 (41.7 %) had subdiaphragmatic inferior vena cava (IVC) tumor thrombus (Group 2), while 13 (9.8 %) had involvement of IVC above diaphragm or atrial extension (Group 3). IVC thrombus was more common from the right-sided tumors. Patients with higher thrombus levels had more blood loss and complicated and longer hospital stay.
Thrombus level was not found to be a predictor of recurrence, ACM and CSM. One- and three-year recurrence-free survivals for non-metastatic patients were 69 and 53 %. Tumor size (p = 0.015), grade (p = 0.007) and venous wall invasion (p = 0.027) were predictors for recurrence. Five-year overall survival was 48, 35 and 13 % for 3 groups, respectively. Presence of distant metastasis (p = 0.032), size (p = 0.002), histology (p = 0.020) and grade (p = 0.013) were predictors of ACM. Five-year cancer-specific survival was 65, 43 and 36 for 3 groups, respectively. Tumor size (p = 0.001) and distant metastasis at presentation (p = 0.025) were the predictors of CSM.
Conclusions
Tumor thrombus level does not predict recurrence or mortality in RCC with venous involvement. Survival is determined by inherent aggressiveness of the cancer manifested by tumor size, grade and distant metastasis at presentation.